Cagrilintide
Fat LossWeight Loss / Metabolic
Long-acting amylin agonist for weight loss; in Phase 3 trials.
For research use only.
Key Facts
- CAS
- Not publicly available
- Molecular Weight (MW)
- ~4749 g/mol
- Half-life
- ~6–7 days
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- 12/18/2025
- Targets
- Amylin receptors (AMYRs)
Overview
Long-acting amylin agonist for weight loss; in Phase 3 trials.
Protocol
- Dosage Range
- 0.1-2.4 mg weekly, titrate up
- Frequency
- Weekly
- Cycle
- 12–20 weeks on, 4 weeks off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 2 mL BAC water for 5 mg vial
Science
Mechanism of Action
Amylin agonism for satiety, gastric delay.
Targets
Amylin receptors (AMYRs)
Studies
- — Journal/year not available
Benefits
Appetite suppressionSustainable weight lossMetabolic improvement
Potential Side Effects
- Nausea
- Vomiting
- Diarrhea